/

Simnorreltir Tablenq/Rironatir Tablenq (co-packaged)
Xiannsoreuei Pian/Lirsonauei Pian Zshebaoxhsang

:(S)-N-((S)- -(S)- )- -((S)- ,
- -( , , - ) )- , - - - [ . ]

C H F N O S

[(αS)-α-[( S, S)- -[( S)- -[ -[( - - - )
]- - ]- - ]- - ] ]

C H N O S

COVID-

Encorafenib

Foqramarinib

Nerarinib

Veneroclav

Δ

CYP A CYP C R- S-

R-

p

/

a

Simnorreltir Tablerq/Rironatir Tablerq (co-packaged)
Xiannsoreuei Pian/Lirsonauei Pian Zshebaoxhsang

p

p

:(S)-N-((S)- - - -((S)- - - - ) )- -((S)- ,
- - -( , , - ) )- , - - - [ . ]
- -

:

C H F N O S

.

p

- [(αS)-α-[( S, S)- - - -[( S)- -[ -[( - - - )
]- - ]- - ]- - ] ]

C H N O S

.

p

p

x sÒ Ĩ COVID- p

s. . ϟ s. N ϟ ᵀ A ᵛ M s ò
Ó Ô
s ò

Ï f

α

u v p

p

p

/

u v p

Nerarinib /

Nerarinib u v p

Veneroclav p

Veneroclav

u v p

/

u v p

3 ⌣ p

3 p

3 p

/ u v - u v p

p

ESRD p u v

p p

eGFR mL/min ESRD p

p p

⌣ p ⌣

p

HIV-1 HIV- HIV- HIV

p

p ⌣ - p

mmol mg p

p

p

p

u v p

p

- mg/kg/ u v p

p

u v p

p

/ p

p / p /

p p

p

u v

p

u v p

SIM - p

B B - p

I

CYP A P-gp p

CYP A P-gp u v u p

/ . g/ . g CYP A

CYP A u v u v p

CYP3A4

mg / . g/ . g Cmav ˘

AUC -r AUC -∞ % % %| % ˘ % %| % % %| % p

CYP A u v p

| | | |
|---|---|---|
| AUC$_{last}$ h³ng/mL | . . % | . % |
| AUC -∞ h³ng/mL | . . % | . % |
| C$_{max}$ ng/mL | . . % | . . % |
| r / h | . - . | . - . |
| T$_{max}$ h | . . - . | . . - . C |

3 -

| mg | mg | AUC | C$_{min}$ |
|---|---|---|---|
| q h | q h | ↑ % | ↑ |
| CYP A p | | mg | |
| mg p | | p | |
| q h | q h | ↑ % | ↑ |
| | | ↑ | ↑ ª |
| CYP A p | | | mg |
| mg p | | p | |
| q h | | ↑ | |
| CYP A p | | | p |
| mg p | | p | |
| q h | q h | ↑ . | ↑ |
| CYP A p | | p | |
| p | mg | mg | |
| p mg | | p | p |
| q h | q h | ↑ % | ND |
| | | ↑ % | ND |
| q h | q h | ↔ | ↑ |
| | | ↔ | ↔ |
| CYP A p | | | |
| p mg | | p | mg |
| mg | | p | |
| q h | q h | ↑ - % | ND |
| | q h | ↑ % | ND |
| | | ↔ | ↔ |
| CYP A p | | | |
| p mg | | p | |
| q h | q h | ↑ | ↑ |
| q h | q h | ↔ | ↔ |
| | | ↑ | ND |
| | | ↔ | ↔ |
| CYP A p | | p | mg |
| mg | | | mg |
| ˘ p | | | |
| mg | mg | mg | |
| - | | | p |
| / p | | p | |
| p | | | |
| q h | q h | ↑ | ↑ |
| | | ↓ % | ND |
| CYP A p | | | p |
| mg | | p | p |

4 -

mg mg

q h q h h ↓ % ↔

↔ ↔

Encorafenib

Foqramarinib

Nerarinib

Veneroclav

Δ

CYP A CYP C R- ↔ S-

R-

p

| | | | | |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | CYP A | | | |
| | | | | |
| Lomirapide | CYP A Lomirapide Lomirapide | | Lomirapide | CYP A Lomirapide |
| | | | | |
| | | | | |
| | | | |

/ mg| mg / mg| mg
Cmav ĻĻQTcF %CI mq ᵖ mgBID
Cmav ĻĻQTcF %CI mq ᵖ
/ ᵖ CYP A
ᵖ
. g Cmav AUC - ₕ AUC -ᵢ ng /mL ng h/mL
ng h/mL T / . h Tmav . h / . g/ . g Cmav
AUC - ₕ AUC -ᵢ ng /mL ng h/mL ng h/mL T / . h Tmav . h
ᵖ / . g/ . g Cmav
AUC - ₕ AUC -ᵢ . g . . . ᵖ

mavma ᵓ ⓦ mav / . g/ . g| . g/ . g
. g| . g Cmav AUC . g| . g
ᵖ / . g/ . g | . g/ . g
Cmav

| | / 0.750g/0.1g N=24 | / 0.750g/0.1g N=12 | / 0.750g/0.1g N=12 |
|---|---|---|---|
| AUC -ᵢ (h³ng/mL) | ( . %) | ( . %) | ( . %) |

| | | | |
|---|---|---|---|
| | ( . %) | ( . %) | ( . %) |
| | ( . %) | ( . %) | ( . %) |
| | . - . | . - . | . - . |
| | . . | . . | ő |

ɹ ʒ

ɹ ʃ

ɹ ʃ

ɹ ʃ